Group B Streptococcus capsular polysaccharide-cholera toxin B subunit conjugate vaccines prepared by different methods for intranasal immunization

Infection and Immunity

Volumn 69, Issue 1, 2001, Pages 297-306

  Shen, X ^a   Lagergard T ^a   Yang, Y ^a   Lindblad, M ^a   Fredriksson, M ^a   Holmgren, J ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL POLYSACCHARIDE; CHOLERA TOXIN B SUBUNIT; CHOLERA VACCINE;

ANIMAL EXPERIMENT; ARTICLE; BACTERIAL MEMBRANE; IMMUNIZATION; INFECTION PREVENTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; STREPTOCOCCUS; STREPTOCOCCUS INFECTION;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL CAPSULES; BACTERIAL VACCINES; CHOLERA TOXIN; FEMALE; IMMUNIZATION; IMMUNOGLOBULIN G; LUNG; MICE; MICE, INBRED C57BL; MOLECULAR WEIGHT; STREPTOCOCCUS AGALACTIAE; VACCINES, CONJUGATE;

EID: 0035158977     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.69.1.297-306.2001     Document Type: Article

References (45)

1. Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib
2. Direct evidence for the involvement of T suppressor cells in the expression of low-dose paralysis to type II Pneumococcal polysaccharide
3. Local and systemic antibody responses to dextran-cholera toxin B subunit conjugates
4. Antibody responses in serum and lung to intranasal immunization with Haemophilus influenzae type b polysaccharide conjugated to cholera toxin B subunit and tetanus toxoid
5. Anticarrier immunity suppresses the antibody response to polysaccharide antigens after intranasal immunization with the polysaccharide-protein conjugate
6. Intranasal vaccination of humans with recombinant cholera toxin B subunit induces systemic and local antibody responses in the upper respiratory tract and the vagina
7. Further studies on the immunogenicity of Haemophilus influenzae type b and pneumococcal type 6A polysaccharide protein conjugates
8. CpG oligodeoxynucleotides act as adjuvants for pneumococcal polysaccharide-protein conjugate vaccine and enhance antipolysaccharide immunoglobulin G2a (IgG2a) and IgG3 antibodies
9. Colorimetric method for determination of sugars and related substances
10. Isotypes of mouse IgG-1. Evidence for "non-complement-fixing" IgG1 antibodies and characterization of their capacity to interfere with IgG2 sensitization of target red blood cells for lysis by complement
11. Comparative immunogenicity of conjugates composed of the Staphylococcus aureus type 8 capsular polysaccharide bound to carrier proteins by adipic acid dihydrazide or N-succinimidyl-3-(2-pyridyldithio)propionate
12. Synthesis and physicochemical and immunological characterization of Pneumococcus type 12F polysaccharidediphtheria toxoid conjugates
13. Prevention of group B streptococcal infection in neonates
14. Interaction of IgG3 anti-streptococcal group A carbohydrate (GAC) antibody with streptococcal group A vaccine: Enhancing and inhibiting effects of anti-GAC, anti-isotypic and anti-idiotypic antibodies
15. Introduction of primary amine
16. Introduction of sulfhydryl residues (thiolation)
17. Strategies for the induction of immune responses at mucosal surfaces making use of cholera toxin B subunit as immunogen, carrier, and adjuvant
18. Cervical secretions in pregnant women colonized rectally with group B streptococci have high levels of antibodies to serotype III polysaccharide capsular antigen and protein R
19. Nasal immunization with group B streptococci can induce high levels of specific IgA antibodies in cervicovaginal secretions of mice
20. Systemic and mucosal immune responses of mice to aluminium-adsorbed or aluminium-non-adsorbed tetanus toxoid administered intranasally with recombinant cholera toxin B subunit
21. Intranasal immunization with pneumococcal polysaccharide conjugate vaccine protects mice against invasive pneumococcal infections
22. Intranasal immunization with pneumococcal polysaccharide conjugate vaccine with nontoxic mutants of Escherichia coli heat-labile enterotoxins as adjuvants protects mice against invasive pneumococcal infections
23. Antibodies and antibody-secreting cells in the female genital tract after vaginal or intranasal immunization with cholera toxin B subunit or conjugate
24. Immune response to type III group B Streptococcal polysaccharide-tetanus toxoid conjugate vaccine
25. Anti-capsular polysaccharide antibodies reduce nasopharyngeal colonization by Haemophilus influenzae type b in infant rats
26. Syntheses and immunologic properties of Escherichia coli O157 O-specific polysaccharide and Shiga toxin 1 B subunit conjugates in mice
27. Safety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults, teenagers, and 2- to 4-year-old children in Vietnam
28. Synthesis and immunological properties of conjugates composed of group B streptococcus type III capsular polysaccharide covalently bound to tetanus toxoid
29. Large-scale production of Vibrio cholerae toxin B subunit for use in oral vaccine
30. Maternal immunization of mice with group B streptococcal type III polysaccharide beta C protein conjugate elicits protective antibody to multiple serotypes
31. Maternal antibody transfer in baboons and mice vaccinated with a Group B Streptococcal polysaccharide conjugate
32. Neonatal mouse protection against infection with multiple group B streptococcal (GBS) serotype by maternal immunization with a tetravalent GBS polysaccharide-tetanus toxoid conjugate vaccine
33. Immunogenicity of a Streptococcus pneumoniae type 4 polysaccharide-protein conjugate vaccine is decreased by admixture of high doses of free saccharide
34. Immunogenicity of Streptococcus pneumoniae type 6B and 14 polysaccharide-tetanus toxoid conjugates and the effect of uncoupled polysaccharide on the antigen-specific immune response
35. Variable region-identical monoclonal antibodies of different IgG subclass directed to Pseudomonas aeruginosa lipopolysaccharide O-specific side chain function differently
36. Group B Streptococcus
37. Epidemiology of group B streptococcal disease in the United States: Shifting paradigms
38. Protective immunity of microsphere-based mucosal vaccines against lethal intranasal challenge with Streptococcus pneumoniae
39. Antigenicity of dextran-protein conjugates in mice: Effect of molecular weight of the carbohydrate and comparison of two modes of coupling
40. Preparation and preclinical evaluation of experimental Group B Streptococcus type III polysaccharide-Cholera toxin B subunit conjugate vaccine for intranasal immunization
41. Systemic and mucosal immunity to group B streptococcus type III capsular polysaccharide conjugate to cholera toxin B subunit after vaccination by different mucosal routes
42. An avidin-biotin based ELISA for quantitation of antibody to bacterial polysaccharides
43. Production of suppressor factor by T cells from mice immunized with Pneumococcal polysaccharide
44. Immunogenicity and protective activity in animals of a type V group B Streptococcal polysaccharide-tetanus toxoid conjugate vaccine
45. Structural properties of group B streptococcal type III polysaccharide conjugate vaccine that influence immunogenicity and efficacy